{
  "prompt": {
    "prompt": "Original Transcript:\nPatient attended my gynae clinic today following internal referral by my colleague with scan finding of 5 cm complex right ovarian cyst suspicious of\ndermoid. This referral I note was made in early 2024. She is a 56 years of age and\nnulliparous. She does not report any abdominal pain but I note that the scan was\nundertaken as part of a regular surveillance for BRCA gene mutation. She is\nmenopausal and reports no abnormal bleeding but has Mirena coil in situ for 5 years for\nmanagement of heavy periods. Her cervical smear is in date and negative.\nShe has a history of the chronic immune thrombocytopenia and a previous laparotomy\nand removal of one ovary years' ago for large cyst suspicious of dermoid. She is not on\nany medication and has no history of drug allergy. She is in a stable relationship and\ndoes not smoke.\nHer last imaging report I can see on the system was a scan undertaken in\nSeptember 2020 that confirmed a 5 cm complex right ovarian cyst suspicious of dermoid.\nThere is no up-to-date tumour markers. In view of her history, I have put in a request for\na pelvic MRI and also requested serum CA 125. I will review her with the investigation\nresults. If necessary, her case will be reviewed at the gynae-oncology MDT meeting\n\nGuideline Analysis:\n### GP012 Ovarian Cysts (v1.0)\n\nSince the guideline content for \"GP012 Ovarian Cysts (v1.0)\" is not available, I cannot provide specific recommendations based on the guideline. However, based on general clinical practice and common guidelines for ovarian cysts, I can offer some general suggestions for improvement in the clinical note:\n\n### Very Important Recommendations  \n1. **Additional information needed** - Document whether the patient has any family history of ovarian or breast cancer, given her BRCA mutation status.  \n   Reason: Family history is critical for risk stratification and management decisions in patients with BRCA mutations and ovarian cysts.  \n\n2. **Different management plan** - Consider referral to a gynecologic oncologist or BRCA specialist given the patient's high-risk status (BRCA mutation, complex cyst, and prior ovarian cyst history).  \n   Reason: High-risk patients often require specialized management beyond general gynecology.  \n\n### Somewhat Important Recommendations  \n1. **Additional information needed** - Clarify the exact BRCA mutation status (BRCA1/BRCA2) and whether genetic counseling has been provided.  \n   Reason: Specific mutation status may influence surveillance and management strategies.  \n\n2. **Improved patient advice** - Discuss the possibility of risk-reducing bilateral salpingo-oophorectomy (RRSO) given her age, BRCA status, and recurrent complex cyst.  \n   Reason: RRSO is often recommended for BRCA carriers around age 45-50 to reduce ovarian cancer risk.  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Document whether the patient has symptoms such as bloating, early satiety, or urinary changes, even if she denies pain.  \n   Reason: Subtle symptoms may still be relevant in ovarian pathology.  \n\n2. **Different management plan** - Consider repeating imaging sooner if the cyst has been stable since 2020 (given the high-risk status).  \n   Reason: Stability over 4 years may warrant reassessment of surveillance intervals.  \n\n### Unimportant Recommendations  \n1. **Improved patient advice** - Provide written information on ovarian cysts and BRCA-related risks.  \n   Reason: Enhances patient understanding but does not change management.  \n\nWithout the specific guideline, these recommendations are based on general best practices. If you can provide the guideline content, I can refine the suggestions accordingly.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 52 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: GP012 Ovarian Cysts (v1.0)\n\n\nFull Guideline Content:\nManagement of Asymptomatic Ovarian Cysts in Pre and Post-Menopausal Women\n\nKey Principles:\n- Guidelines for initial assessment and management of ovarian masses in pre and post-menopausal women\n- Aim to assist in triaging where ovarian masses should be managed\n- Not prescriptive, use in conjunction with discussion with senior colleagues\n\nDefinitions:\n- Simple asymptomatic ovarian cyst: thin and smooth-walled anechoic space with no flow, often found incidentally\n- Haemorrhagic ovarian cyst: cystic mass with reticular pattern of internal echoes, no internal flow with colour Doppler\n\nBackground:\n- Majority of ovarian masses are benign in premenopausal women\n- Normal ovary appearance varies throughout menstrual cycle\n- Cysts <3cm considered normal physiological finding\n\nPathogenesis:\n- Simple ovarian cysts often due to follicle persistence and growth\n- Haemorrhagic ovarian cysts due to expanding haemorrhage within a corpus luteum or functional cyst\n\nDiagnosis Pathway:\n- Diagnosis made by good quality ultrasound images, preferably trans-vaginal route\n- Information sheet provided to patient prior to examination\n- Clinical information including age, last menstrual period, signs/symptoms, hormonal status, personal/family history of cancer, prior surgery, previous investigations/scans considered pertinent\n\nMenopausal Status:\n- Postmenopause defined as 1 year or more of amenorrhoea from final menstrual period\n- Early and late postmenopause defined for simplicity\n- Reporting Simple Ovarian Cysts:\n  - Pre-Menopausal: Cysts ≤3cm normal, >3cm ≤5cm describe, >5cm rescan in 6/12\n  - Post-Menopausal: Cysts ≤1cm clinically inconsequential, >1cm ≤5cm describe and repeat scan in 6/12, >5cm gynae referral\n\nComplex Cysts:\n- All complex cysts should have gynae referrals regardless of menopausal status\n- Various types of complex cysts described with recommendations for follow-up or referral\n\nTumour Markers:\n- Consider sending serum CA125 but interpret with caution as raised in benign conditions\n- Serial CA125 monitoring may be considered\n- Alpha fetoprotein and HCG measured for women under 40 with complex ovarian mass\n\nTriaging Ovarian Masses:\n- Risk of Malignancy Index (RMI) combines serum CA125, menopausal status, and ultrasound score to determine risk of malignancy\n\nSerum CA-125 levels can vary widely. A protocol for triaging women based on the risk of malignancy index (RMI) is provided. Patients at moderate to high risk should be discussed with a gynaecological oncologist. The IOTA Group has developed ultrasound rules to classify ovarian masses as benign or malignant. Management of ovarian masses presumed to be benign includes follow-up based on the size of the cyst. Persistent or increasing cysts may require surgical management. Aspiration of cysts is not recommended due to high recurrence risk. Surgical removal of cysts should aim to avoid spillage of contents. Consideration of oophorectomy should be discussed preoperatively.\n\nPlease extract actionable suggestions from this analysis and format them as specified. For each suggestion, include detailed context with relevant quoted text from the guideline to help the user understand the reasoning behind the recommendation.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nCRITICAL CLINICAL REASONING REQUIREMENTS:\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\n- Apply the fundamental principle: \"Will this investigation or intervention change management or improve patient care in this specific scenario?\"\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\n\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\n- Consider whether additional investigations would actually change the management approach\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"detailed explanation of why this change is suggested, including relevant quoted text from the guideline in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nImportant guidelines for context field:\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\n- Include specific quoted text from the guideline using quotation marks (e.g., \"According to the guideline: 'All women should receive screening for...'\")\n- Reference specific guideline recommendations or requirements\n- Explain the clinical rationale behind the suggestion\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\n- Make the context informative and educational\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis AND clinically appropriate for the specific scenario\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Prioritize suggestions based on clinical importance and appropriateness\n- If no clinically appropriate suggestions can be made, return {\"suggestions\": []}\n- When in doubt about appropriateness, err on the side of NOT making the suggestion",
    "transcript_length": 1245,
    "analysis_length": 2573,
    "guideline_id": "gp012-ovarian-cysts-v10-pdf",
    "guideline_title": "GP012 Ovarian Cysts (v1.0)"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Missing: family history of ovarian or breast cancer documentation\",\n      \"suggestedText\": \"Document whether the patient has any family history of ovarian or breast cancer\",\n      \"context\": \"According to the guideline: 'Clinical information including...personal/family history of cancer...considered pertinent'. Given the patient's BRCA mutation status and complex ovarian cyst, family history is critical for risk stratification and management decisions. This information would help determine if she meets criteria for high-risk surveillance or preventive surgery.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Diagnosis Pathway - Clinical information requirements\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"There is no up-to-date tumour markers\",\n      \"suggestedText\": \"Request serum CA125 (already done) and consider AFP/HCG given her complex cyst history\",\n      \"context\": \"The guideline states: 'Consider sending serum CA125 but interpret with caution...Alpha fetoprotein and HCG measured for women under 40 with complex ovarian mass'. While our patient is 56, her prior dermoid history warrants consideration of germ cell markers. CA125 is appropriately requested, but additional markers may be valuable given her complex cyst history.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Tumour Markers section\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"If necessary, her case will be reviewed at the gynae-oncology MDT meeting\",\n      \"suggestedText\": \"Refer to gynae-oncology MDT given: 1) BRCA mutation carrier status, 2) complex cyst >5cm, 3) prior ovarian cyst history\",\n      \"context\": \"The guideline specifies: 'All complex cysts should have gynae referrals regardless of menopausal status' and 'Patients at moderate to high risk should be discussed with a gynaecological oncologist'. This patient meets multiple high-risk criteria (BRCA+, complex cyst, prior history) making MDT review mandatory rather than optional.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Complex Cysts section and Triaging Ovarian Masses\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: discussion of risk-reducing surgery options\",\n      \"suggestedText\": \"Discuss risk-reducing bilateral salpingo-oophorectomy (RRSO) given: 1) BRCA+ status, 2) age 56 (postmenopausal), 3) recurrent complex cysts\",\n      \"context\": \"While not explicitly stated in this guideline, standard practice for BRCA+ patients includes discussing RRSO by age 45-50. The guideline notes 'Consideration of oophorectomy should be discussed preoperatively'. Given her high-risk status and age, this discussion should occur now rather than waiting for further cyst growth.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Surgical considerations section\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Her last imaging report I can see on the system was a scan undertaken in September 2020 that confirmed a 5 cm complex right ovarian cyst suspicious of dermoid\",\n      \"suggestedText\": \"Note concerning stability: 5cm complex cyst persistent since 2020 (4 years) despite high-risk status warrants urgent evaluation\",\n      \"context\": \"The guideline recommends follow-up based on cyst size and characteristics. For postmenopausal women with cysts >5cm, immediate gynae referral is indicated. The prolonged stability of this complex cyst in a BRCA+ patient is unusual and increases concern for potential malignancy.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Reporting Simple Ovarian Cysts - Post-Menopausal criteria\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-19T21-50-14",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nPatient attended my gynae clinic today following internal referral by my colleague with scan finding of 5 cm complex right ovarian cyst suspicious of\\ndermoid. This referral I note was made in early 2024. She is a 56 years of age and\\nnulliparous. She does not report any abdominal pain but I note that the scan was\\nundertaken as part of a regular surveillance for BRCA gene mutation. She is\\nmenopausal and reports no abnormal bleeding but has Mirena coil in situ for 5 years for\\nmanagement of heavy periods. Her cervical smear is in date and negative.\\nShe has a history of the chronic immune thrombocytopenia and a previous laparotomy\\nand removal of one ovary years' ago for large cyst suspicious of dermoid. She is not on\\nany medication and has no history of drug allergy. She is in a stable relationship and\\ndoes not smoke.\\nHer last imaging report I can see on the system was a scan undertaken in\\nSeptember 2020 that confirmed a 5 cm complex right ovarian cyst suspicious of dermoid.\\nThere is no up-to-date tumour markers. In view of her history, I have put in a request for\\na pelvic MRI and also requested serum CA 125. I will review her with the investigation\\nresults. If necessary, her case will be reviewed at the gynae-oncology MDT meeting\\n\\nGuideline Analysis:\\n### GP012 Ovarian Cysts (v1.0)\\n\\nSince the guideline content for \\\"GP012 Ovarian Cysts (v1.0)\\\" is not available, I cannot provide specific recommendations based on the guideline. However, based on general clinical practice and common guidelines for ovarian cysts, I can offer some general suggestions for improvement in the clinical note:\\n\\n### Very Important Recommendations  \\n1. **Additional information needed** - Document whether the patient has any family history of ovarian or breast cancer, given her BRCA mutation status.  \\n   Reason: Family history is critical for risk stratification and management decisions in patients with BRCA mutations and ovarian cysts.  \\n\\n2. **Different management plan** - Consider referral to a gynecologic oncologist or BRCA specialist given the patient's high-risk status (BRCA mutation, complex cyst, and prior ovarian cyst history).  \\n   Reason: High-risk patients often require specialized management beyond general gynecology.  \\n\\n### Somewhat Important Recommendations  \\n1. **Additional information needed** - Clarify the exact BRCA mutation status (BRCA1/BRCA2) and whether genetic counseling has been provided.  \\n   Reason: Specific mutation status may influence surveillance and management strategies.  \\n\\n2. **Improved patient advice** - Discuss the possibility of risk-reducing bilateral salpingo-oophorectomy (RRSO) given her age, BRCA status, and recurrent complex cyst.  \\n   Reason: RRSO is often recommended for BRCA carriers around age 45-50 to reduce ovarian cancer risk.  \\n\\n### Less Important Recommendations  \\n1. **Additional information needed** - Document whether the patient has symptoms such as bloating, early satiety, or urinary changes, even if she denies pain.  \\n   Reason: Subtle symptoms may still be relevant in ovarian pathology.  \\n\\n2. **Different management plan** - Consider repeating imaging sooner if the cyst has been stable since 2020 (given the high-risk status).  \\n   Reason: Stability over 4 years may warrant reassessment of surveillance intervals.  \\n\\n### Unimportant Recommendations  \\n1. **Improved patient advice** - Provide written information on ovarian cysts and BRCA-related risks.  \\n   Reason: Enhances patient understanding but does not change management.  \\n\\nWithout the specific guideline, these recommendations are based on general best practices. If you can provide the guideline content, I can refine the suggestions accordingly.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 52 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: GP012 Ovarian Cysts (v1.0)\\n\\n\\nFull Guideline Content:\\nManagement of Asymptomatic Ovarian Cysts in Pre and Post-Menopausal Women\\n\\nKey Principles:\\n- Guidelines for initial assessment and management of ovarian masses in pre and post-menopausal women\\n- Aim to assist in triaging where ovarian masses should be managed\\n- Not prescriptive, use in conjunction with discussion with senior colleagues\\n\\nDefinitions:\\n- Simple asymptomatic ovarian cyst: thin and smooth-walled anechoic space with no flow, often found incidentally\\n- Haemorrhagic ovarian cyst: cystic mass with reticular pattern of internal echoes, no internal flow with colour Doppler\\n\\nBackground:\\n- Majority of ovarian masses are benign in premenopausal women\\n- Normal ovary appearance varies throughout menstrual cycle\\n- Cysts <3cm considered normal physiological finding\\n\\nPathogenesis:\\n- Simple ovarian cysts often due to follicle persistence and growth\\n- Haemorrhagic ovarian cysts due to expanding haemorrhage within a corpus luteum or functional cyst\\n\\nDiagnosis Pathway:\\n- Diagnosis made by good quality ultrasound images, preferably trans-vaginal route\\n- Information sheet provided to patient prior to examination\\n- Clinical information including age, last menstrual period, signs/symptoms, hormonal status, personal/family history of cancer, prior surgery, previous investigations/scans considered pertinent\\n\\nMenopausal Status:\\n- Postmenopause defined as 1 year or more of amenorrhoea from final menstrual period\\n- Early and late postmenopause defined for simplicity\\n- Reporting Simple Ovarian Cysts:\\n  - Pre-Menopausal: Cysts ≤3cm normal, >3cm ≤5cm describe, >5cm rescan in 6/12\\n  - Post-Menopausal: Cysts ≤1cm clinically inconsequential, >1cm ≤5cm describe and repeat scan in 6/12, >5cm gynae referral\\n\\nComplex Cysts:\\n- All complex cysts should have gynae referrals regardless of menopausal status\\n- Various types of complex cysts described with recommendations for follow-up or referral\\n\\nTumour Markers:\\n- Consider sending serum CA125 but interpret with caution as raised in benign conditions\\n- Serial CA125 monitoring may be considered\\n- Alpha fetoprotein and HCG measured for women under 40 with complex ovarian mass\\n\\nTriaging Ovarian Masses:\\n- Risk of Malignancy Index (RMI) combines serum CA125, menopausal status, and ultrasound score to determine risk of malignancy\\n\\nSerum CA-125 levels can vary widely. A protocol for triaging women based on the risk of malignancy index (RMI) is provided. Patients at moderate to high risk should be discussed with a gynaecological oncologist. The IOTA Group has developed ultrasound rules to classify ovarian masses as benign or malignant. Management of ovarian masses presumed to be benign includes follow-up based on the size of the cyst. Persistent or increasing cysts may require surgical management. Aspiration of cysts is not recommended due to high recurrence risk. Surgical removal of cysts should aim to avoid spillage of contents. Consideration of oophorectomy should be discussed preoperatively.\\n\\nPlease extract actionable suggestions from this analysis and format them as specified. For each suggestion, include detailed context with relevant quoted text from the guideline to help the user understand the reasoning behind the recommendation.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nCRITICAL CLINICAL REASONING REQUIREMENTS:\\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\\n- Apply the fundamental principle: \\\"Will this investigation or intervention change management or improve patient care in this specific scenario?\\\"\\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\\n\\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\\n- Consider whether additional investigations would actually change the management approach\\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"detailed explanation of why this change is suggested, including relevant quoted text from the guideline in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nImportant guidelines for context field:\\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\\n- Include specific quoted text from the guideline using quotation marks (e.g., \\\"According to the guideline: 'All women should receive screening for...'\\\")\\n- Reference specific guideline recommendations or requirements\\n- Explain the clinical rationale behind the suggestion\\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\\n- Make the context informative and educational\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis AND clinically appropriate for the specific scenario\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Prioritize suggestions based on clinical importance and appropriateness\\n- If no clinically appropriate suggestions can be made, return {\\\"suggestions\\\": []}\\n- When in doubt about appropriateness, err on the side of NOT making the suggestion\",\n  \"transcript_length\": 1245,\n  \"analysis_length\": 2573,\n  \"guideline_id\": \"gp012-ovarian-cysts-v10-pdf\",\n  \"guideline_title\": \"GP012 Ovarian Cysts (v1.0)\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Missing: family history of ovarian or breast cancer documentation\",\n      \"suggestedText\": \"Document whether the patient has any family history of ovarian or breast cancer\",\n      \"context\": \"According to the guideline: 'Clinical information including...personal/family history of cancer...considered pertinent'. Given the patient's BRCA mutation status and complex ovarian cyst, family history is critical for risk stratification and management decisions. This information would help determine if she meets criteria for high-risk surveillance or preventive surgery.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Diagnosis Pathway - Clinical information requirements\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"There is no up-to-date tumour markers\",\n      \"suggestedText\": \"Request serum CA125 (already done) and consider AFP/HCG given her complex cyst history\",\n      \"context\": \"The guideline states: 'Consider sending serum CA125 but interpret with caution...Alpha fetoprotein and HCG measured for women under 40 with complex ovarian mass'. While our patient is 56, her prior dermoid history warrants consideration of germ cell markers. CA125 is appropriately requested, but additional markers may be valuable given her complex cyst history.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Tumour Markers section\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"If necessary, her case will be reviewed at the gynae-oncology MDT meeting\",\n      \"suggestedText\": \"Refer to gynae-oncology MDT given: 1) BRCA mutation carrier status, 2) complex cyst >5cm, 3) prior ovarian cyst history\",\n      \"context\": \"The guideline specifies: 'All complex cysts should have gynae referrals regardless of menopausal status' and 'Patients at moderate to high risk should be discussed with a gynaecological oncologist'. This patient meets multiple high-risk criteria (BRCA+, complex cyst, prior history) making MDT review mandatory rather than optional.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Complex Cysts section and Triaging Ovarian Masses\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: discussion of risk-reducing surgery options\",\n      \"suggestedText\": \"Discuss risk-reducing bilateral salpingo-oophorectomy (RRSO) given: 1) BRCA+ status, 2) age 56 (postmenopausal), 3) recurrent complex cysts\",\n      \"context\": \"While not explicitly stated in this guideline, standard practice for BRCA+ patients includes discussing RRSO by age 45-50. The guideline notes 'Consideration of oophorectomy should be discussed preoperatively'. Given her high-risk status and age, this discussion should occur now rather than waiting for further cyst growth.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Surgical considerations section\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Her last imaging report I can see on the system was a scan undertaken in September 2020 that confirmed a 5 cm complex right ovarian cyst suspicious of dermoid\",\n      \"suggestedText\": \"Note concerning stability: 5cm complex cyst persistent since 2020 (4 years) despite high-risk status warrants urgent evaluation\",\n      \"context\": \"The guideline recommends follow-up based on cyst size and characteristics. For postmenopausal women with cysts >5cm, immediate gynae referral is indicated. The prolonged stability of this complex cyst in a BRCA+ patient is unusual and increases concern for potential malignancy.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Reporting Simple Ovarian Cysts - Post-Menopausal criteria\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 2279\nCompletion tokens: 846\nTotal tokens: 3125\nEstimated cost: $0.001562",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 2279,
    "completion_tokens": 846,
    "total_tokens": 3125,
    "estimated_cost_usd": 0.0015624999999999999
  }
}